1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Lau, G.; Sangro, B.; Crysler, O. V.; Sukeepaisarnjaroen, W.; Lipatov, O.; Morimoto, Ma.; Archambeaud, I.; Burgio, V.; Tuyet Phuong, L. T.; Chao, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
    Meeting Abstract

    Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Solit, D. B.; Walch, H. S.; Chatila, W. K.; Maron, S. B.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Schultz, N.; Berger, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
    Meeting Abstract

    Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla Mercade, T.; Xie, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
    Meeting Abstract

    O'Reilly, E. M.; Melisi, D.; Macarulla, T.; Pazo Cid, R. A.; Chandana, S. R.; De La Fouchardiere, C.; Dean, A. P.; Kiss, I.; Lee, W. J.; Goetze, T. O.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
    Meeting Abstract

    Cohen, R.; Raeisi, M.; Shi, Q.; Chibaudel, B.; Yoshino, T.; Zalcberg, J. R.; Adams, R.; Cremolini, C.; Van Cutsem, E.; Heinemann, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Lau, G.; Cheng, A. L.; Sangro, B.; Kudo, M.; Kelley, R. K.; Tak, W. Y.; Gasbarrini, A.; Reig, M.; Lim, H. Y.; Tougeron, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy
    Meeting Abstract

    Judge, S.; Malekzadeh, P.; Corines, M. J.; Gollub, M. J.; Horvat, N.; Saltz, L. B.; Cercek, A.; Romesser, P. B.; Crane, C. H.; Wei, I. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save